Corvida Medical’s Halo® Closed System Transfer Device (CSTD) has been shown to reduce surface contamination in both the mixing and administration of antineoplastic hazardous drugs (AHDs) in a thirteen center US site study. The results of the study, which was made possible through an NCI-Funded SBIR grant, were revealed in a poster presentation on March 30, 2017 at the annual Hematology Oncology Pharmacists Association annual conference.
The Poster Presentation, Assessment of a New CSTD at 13 U.S. Cancer Centers was authored by Timothy G. Tyler, PharmD (Comprehensive Cancer Center, Desert Regional Medical Center, Palm Springs, CA); Sylvia B. Bartel, RPh, MPH (Dana-Farber Cancer Institute, Boston, MA); and Luci A. Power, RPh, MS (Power Enterprises, San Francisco, CA). The thirteen study sites were recruited from National Cancer Institute (NCI) Designated Cancer Centers and the members of the Association of Community Cancer Centers (ACCC) in the US.